The invention relates to variants of the urokinase plasminogen activator receptor (uPAR) that display remarkably increased vitronectin (VN) binding activity possibly caused by a more efficient exposure of the VN binding site. The present invention also refers to antibodies raised against said uPAR variants able to bind to the VN binding site of uPAR and then acting as inhibitors of uPAR functions acting as functional antagonists of VN activated uPAR functions. In the present invention such antibodies are monoclonal polyclonal synthetic or recombinant derivatives thereof as synthetic antibodies (scFv) from phage display libraries. Antibodies of the invention act as competitive antagonists.
